Head-to-head · Cost-Efficiency Index
Effecty vs Eden
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Effecty
People who want competitive compounded pricing but also the option to step up to brand-name, verified and nationwide.
Visit EffectyEden
People who will trade a higher sticker price for verified nationwide access and stronger clinical oversight.
Visit EdenThe verdict
Effecty and Eden tie on the Cost-Efficiency Index at 86/100, so neither wins outright on the numbers. For most shoppers we'd start with Effecty (ranked #14, a hair above #15) — People who want competitive compounded pricing but also the option to step up to brand-name, verified and nationwide. But Eden is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Effecty.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Effecty | Eden |
|---|---|---|
| Cost-Efficiency Index | 86/100 | 86/100 |
| Semaglutide / mo | $160/mo | $239/mo |
| Tirzepatide / mo | $240/mo | $349/mo |
| Semaglutide / yr (modeled) | $1,920 | $2,868 |
| Tirzepatide / yr (modeled) | $2,880 | $4,188 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #14 | #15 |
Effecty
86/100Where the value is
- Both molecules disclosed at competitive prices with all-50 access
- Offers FDA-approved brand-name access alongside compounded
- LegitScript-certified pharmacy
The tradeoffs
- Per-month cost is mid-market, not budget-tier
- No oral/sublingual option
Eden
86/100Where the value is
- High transparency — clear supply-chain and clinician disclosure lowers hidden-cost risk
- Nationwide availability with both molecules disclosed
- Strong clinical oversight adds value beyond the raw price
The tradeoffs
- Premium per-month cost drags its normalized value score
- Compounded only — no brand-name access
Regulatory note: the FDA issued a warning letter to Eden Health International Inc. dba Eden in June 2026. We still list and link to Eden; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.